γ‐Glutamyl transpeptidase from equine kidney (ekGGT, E.C. 2.3.2.2) is an intrinsic membrane enzyme which transfers the γ‐glutamyl moiety of glutathione to amino acids and peptides, thus producing γ‐glutamyl derivatives. An immobilization study of ekGGT was carried out with the aim to develop a robust biocatalyst for the synthesis of γ‐glutamyl amino acids which are known as kokumi compounds. Heterofunctional
those of authentic peptides prepared using chemical methods. Mass spectrometric analysis also enabled determination of the linkage modes in the glutamyl dipeptides by their characteristic fragmentation. In sensory evaluation, these peptides exhibited flavor-modifying effects (continuity) in umami solutions less pronounced but similar to that of glutathione. Furthermore, the peptides exhibited intrinsic
γ-Glutamyltranspeptidases in the metabolism of γ-glutamyl peptides in plants
作者:Takanori Kasai、Akemi Ohmiya、Sadao Sakamura
DOI:10.1016/0031-9422(82)80117-9
日期:1982.1
Abstract The activity and specificity of γ-glutamyltranspeptidase in immature seeds of some leguminous plants did not reflect the γ-glutamylpeptide pattern
摘要 一些豆科植物未成熟种子中γ-谷氨酰转肽酶的活性和特异性并未反映γ-谷氨酰肽模式。
Enzymatic Synthesis of γ‐Glutamyl Dipeptides Catalysed by Mutant
<i>E. coli</i>
γ‐Glutamyltransferases
作者:Marco Rabuffetti、Giovanna Speranza、Cinzia Calvio、Carlo F. Morelli
DOI:10.1002/ejoc.202200907
日期:2022.11.18
identified inside the active site of E. coli γ-glutamyltransferase, putatively involved in acceptor substrate binding. Point-mutation of these residues afforded two mutant enzymes with altered catalytic properties. Mutant T413L showed a very promising transpeptidation-to-hydrolysis ratio up to 20 : 1. The two mutants were tested as biocatalysts for the enzymatic synthesis of γ-glutamyl dipeptides with flavor-enhancer
NOVEL STRAIN OF BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS CECT 8145 AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF EXCESS WEIGHT AND OBESITY AND ASSOCIATED DISEASES
申请人:Biopolis, S.L.
公开号:EP3048165A1
公开(公告)日:2016-07-27
The invention is applicable within the food and pharmaceutical industry. More specifically, it relates to a novel strain of the species Bifidobacterium animalis subsp. lactis CECT 8145, the cell components, metabolites and secreted molecules thereof, which, incorporated into food and/or pharmaceutical formulations, can be used in the treatment and/or prevention of excess weight and obesity and related diseases such as metabolic syndrome, hypertension, glycemia, inflammation, type 2 diabetes, cardiovascular diseases, hypercholesterolemia, hormonal alterations, infertility, etc.